Association Between SARS-CoV-2 Infection During Pregnancy and Gestational Diabetes: A Claims-based Cohort Study.

IF 8.2 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2024-12-17 DOI:10.1093/cid/ciae416
Oscar Rincón-Guevara, Bailey Wallace, Lyudmyla Kompaniyets, Catherine E Barrett, Lara Bull-Otterson
{"title":"Association Between SARS-CoV-2 Infection During Pregnancy and Gestational Diabetes: A Claims-based Cohort Study.","authors":"Oscar Rincón-Guevara, Bailey Wallace, Lyudmyla Kompaniyets, Catherine E Barrett, Lara Bull-Otterson","doi":"10.1093/cid/ciae416","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Coronavirus disease 2019 (COVID-19) may be associated with gestational diabetes mellitus (GDM); however, evidence is limited by sample sizes and lack of control groups.</p><p><strong>Methods: </strong>To assess the GDM risk after COVID-19 in pregnancy, we constructed a retrospective cohort of pregnancies ending March 2020-October 2022 using medical claims. People with COVID-19 diagnosis claims from conception to 21 gestational weeks (n = 57 675) were matched 1:2 to those without COVID-19 during pregnancy (n = 115 350) by age range, pregnancy start month, and encounter year-month. GDM (claim ≥23 gestational weeks) relative risk and risk difference overall, by race and ethnicity, and variant period were estimated using log-binomial models.</p><p><strong>Results: </strong>GDM risk was higher among those with COVID-19 during pregnancy compared to those without (adjusted risk ratio [aRR] = 1.12; 95% confidence interval [CI], 1.08-1.15). GDM risk was significantly associated with COVID-19 in non-Hispanic White (aRR = 1.08; 95% CI, 1.04-1.14), non-Hispanic Black (aRR = 1.15; 95% CI, 1.07-1.24), and Hispanic (aRR = 1.17; 95% CI, 1.10-1.24) groups. GDM risk was significantly higher during pre-Delta (aRR = 1.17; 95% CI, 1.11-1.24) compared to Omicron (aRR = 1.07; 95% CI, 1.02-1.13) periods, but neither differed from the Delta period (aRR = 1.10; 95% CI, 1.04-1.17). The adjusted risk difference was 0%-2% for all models.</p><p><strong>Conclusions: </strong>COVID-19 during pregnancy was modestly associated with GDM in claims-based data, especially during earlier SARS-CoV-2 variant periods. Because these associations are based on COVID-19 in claims data, studies employing systematic testing are warranted.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1386-1393"},"PeriodicalIF":8.2000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae416","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) may be associated with gestational diabetes mellitus (GDM); however, evidence is limited by sample sizes and lack of control groups.

Methods: To assess the GDM risk after COVID-19 in pregnancy, we constructed a retrospective cohort of pregnancies ending March 2020-October 2022 using medical claims. People with COVID-19 diagnosis claims from conception to 21 gestational weeks (n = 57 675) were matched 1:2 to those without COVID-19 during pregnancy (n = 115 350) by age range, pregnancy start month, and encounter year-month. GDM (claim ≥23 gestational weeks) relative risk and risk difference overall, by race and ethnicity, and variant period were estimated using log-binomial models.

Results: GDM risk was higher among those with COVID-19 during pregnancy compared to those without (adjusted risk ratio [aRR] = 1.12; 95% confidence interval [CI], 1.08-1.15). GDM risk was significantly associated with COVID-19 in non-Hispanic White (aRR = 1.08; 95% CI, 1.04-1.14), non-Hispanic Black (aRR = 1.15; 95% CI, 1.07-1.24), and Hispanic (aRR = 1.17; 95% CI, 1.10-1.24) groups. GDM risk was significantly higher during pre-Delta (aRR = 1.17; 95% CI, 1.11-1.24) compared to Omicron (aRR = 1.07; 95% CI, 1.02-1.13) periods, but neither differed from the Delta period (aRR = 1.10; 95% CI, 1.04-1.17). The adjusted risk difference was 0%-2% for all models.

Conclusions: COVID-19 during pregnancy was modestly associated with GDM in claims-based data, especially during earlier SARS-CoV-2 variant periods. Because these associations are based on COVID-19 in claims data, studies employing systematic testing are warranted.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
孕期感染 SARS-CoV-2 与妊娠糖尿病之间的关系:一项基于索赔的队列研究。
导言:2019年冠状病毒病(COVID-19)可能与妊娠糖尿病(GDM)有关;然而,由于样本量和缺乏对照组,证据有限:为了评估妊娠期感染 COVID-19 后的 GDM 风险,我们利用医疗索赔建立了一个回顾性队列,涵盖 2020 年 3 月至 2022 年 10 月的妊娠。按照年龄范围、妊娠开始月份和妊娠年月,将从受孕到 21 孕周期间有 COVID-19 诊断索赔的人(n = 57,675)与怀孕期间没有 COVID-19 诊断的人(n = 115,350)进行 1:2 匹配。使用对数二项式模型估算了GDM(孕周≥23)的总体相对风险和风险差异,并按种族、民族和变异期进行了分类:结果:与没有 COVID-19 的孕妇相比,孕期有 COVID-19 的孕妇发生 GDM 的风险更高(调整风险比 aRR = 1.12,95% CI:1.08-1.15)。在非西班牙裔(NH)白人(aRR = 1.08,95% CI:1.04-1.14)、NH 黑人(aRR=1.15,95% CI:1.07-1.24)和西班牙裔(aRR = 1.17,95% CI:1.10-1.24)群体中,GDM 风险与 COVID-19 显著相关。与 Omicron(aRR = 1.07,95% CI:1.02-1.13)时期相比,Delta 前(aRR = 1.17,95% CI:1.11-1.24)时期的 GDM 风险明显更高,但与 Delta 时期(aRR = 1.10,95% CI:1.04-1.17)相比,两者均无差异。所有模型的调整后风险差异均为 0-2%:结论:在基于理赔的数据中,孕期 COVID-19 与 GDM 的关系不大,尤其是在较早的 SARS-CoV-2 变异期间。由于这些关联是基于索赔数据中的 COVID-19 而得出的,因此有必要进行系统的测试研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study. Comparative Outcomes of Babesiosis in Immunocompromised and Non-Immunocompromised Hosts: A Multicenter Cohort Study. Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1